公开(公告)号：HK1171766A1

公开(公告)日：2013-04-05

申请号：HK12112366

申请日：2012-11-30

Applicant: ACADEMIA SINICA

Inventor： CHANG TSEWEN ,  CHEN JIUN-BO ,  WU PHEIDIAS C C ,  HUNG ALFUR F F

IPC: C07K20060101 ,  A61K20060101 ,  A61P20060101

公开(公告)号：BRPI1008317B1

公开(公告)日：2022-05-03

申请号：BRPI1008317

申请日：2010-02-25

Applicant: ACADEMIA SINICA

Inventor： ALFUR F HUNG ,  CHEN JIUN-BO ,  PHEIDIAS C WU ,  CHANG TSEWEN

IPC: A61K39/395 ,  A61K38/10 ,  A61P37/00 ,  C07K16/28

Abstract: anticorpo c?mx-específico ou fragmento de ligação ao antígeno, uso dos mesmos e uso de imunogênicos. a invenção está relacionada à geração e utilidade de anticorpos que podem eficazmente se ligar ao domínio c?mx em ige ligado a membrana (mlge) expressos na superfície de linfócitos b humanos. o domínio c?mx de 52 resíduos de aminoácidos, localizado entre o domínio ch4 e o peptídeo de ancoragem de membrana c-terminal na cadeia epsiion ligada à membrana humana. foi sugerido como um sítio antigênico para alvo imunológico de células b expressando mige. anticorpos monoclonais anteriormente reportados, incluindo a20, que se liga ao peptídeo radwpgpp no c-terminal de c?mx, foram verificados que se ligam fracamente a mige em células b humanas. os presentes inventores verificaram agora que apenas anticorpos monoclonais específicos para certos segmentos, tais como glaggsaqsqrapdrvl e hsgqqqglpraaggsvphprde c?mx podem se ligar eficazmente a mige sobre as células b humanas e, portanto, terem utilidade para atingir aquelas células b para o tratamento de doenças mediadas por ige.

公开(公告)号：DK3157951T3

公开(公告)日：2020-08-17

申请号：DK15810347

申请日：2015-06-16

Applicant: ACADEMIA SINICA

Inventor： CHEN JIUN-BO ,  SHIUNG YU-YU ,  CHANG TSE-WEN

IPC: C07K16/42 ,  A61P37/06

公开(公告)号：CA2943588C

公开(公告)日：2019-04-30

申请号：CA2943588

申请日：2015-06-16

Applicant: ACADEMIA SINICA

Inventor： CHEN JIUN-BO ,  SHIUNG YU-YU ,  CHANG TSE-WEN

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/42 ,  C07K16/46

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

公开(公告)号：PL2401300T3

公开(公告)日：2018-07-31

申请号：PL10745796

申请日：2010-02-25

Applicant: ACADEMIA SINICA

Inventor： CHANG TSE WEN ,  CHEN JIUN-BO ,  WU PHEIDIAS C ,  HUNG ALFUR F

IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00 ,  C07K16/42

公开(公告)号：ES2665495T3

公开(公告)日：2018-04-26

申请号：ES10745796

申请日：2010-02-25

Applicant: ACADEMIA SINICA

Inventor： CHANG TSE WEN ,  CHEN JIUN-BO ,  WU PHEIDIAS ,  HUNG ALFUR

IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00 ,  C07K16/42

Abstract: Un anticuerpo específico para CεmX o un fragmento del mismo, que es capaz de unirse a IgE unida a la membrana sobre linfocitos B humanos e incapaz de unirse al péptido RADWPGPP, en donde el anticuerpo o el fragmento del mismo se une a GLAGGSAQSQRAPDRVL (SEQ ID Nº: 2).

公开(公告)号：AU2015277379B2

公开(公告)日：2017-06-29

申请号：AU2015277379

申请日：2015-06-16

Applicant: ACADEMIA SINICA

Inventor： CHEN JIUN-BO ,  SHIUNG YU-YU ,  CHANG TSE-WEN

IPC: C07K16/00 ,  A61K39/00 ,  C12P21/08

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

公开(公告)号：EP2838919A4

公开(公告)日：2016-03-23

申请号：EP13778472

申请日：2013-03-14

Applicant: ACADEMIA SINICA

Inventor： CHANG TSE WEN ,  CHEN JIUN-BO ,  LIN CHIEN-JEN ,  CHEN NIEN-YI

IPC: C07K16/18 ,  A61K39/395 ,  A61P37/00 ,  C07K16/42 ,  C12N15/13

CPC classification number: C07K16/4291 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732

公开(公告)号：EP2401300A4

公开(公告)日：2013-01-23

申请号：EP10745796

申请日：2010-02-25

Applicant: ACADEMIA SINICA

Inventor： CHANG TSEWEN ,  CHEN JIUN-BO ,  WU PHEIDIAS C ,  HUNG ALFUR F

IPC: C07K16/28 ,  A61K38/10 ,  A61K39/395 ,  A61P37/00 ,  C07K16/42

CPC classification number: C07K16/2803 ,  A61K39/39566 ,  C07K16/4291 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  Y10S424/805 ,  Y10S424/81 ,  Y10S530/862 ,  Y10S530/868

Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to CepsilonmX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The CepsilonmX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of CepsilonmX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of CepsilonmX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.

Abstract translation: 本发明涉及可在人B淋巴细胞表面表达的膜结合IgE（mIgE）上有效结合CepsilonmX结构域的抗体的产生和应用。 已经提出位于人膜结合的ε链上的CH4结构域和C末端膜锚定肽之间的52个氨基酸残基的Cepsilonm结构域作为用于免疫靶向表达mIgE的B细胞的抗原位点。 现在已经发现，先前报道的包含与CepsilonmX C末端的RADWPGPP（SEQ ID NO：1）肽结合的α20的单克隆抗体已经发现与人B细胞上的mIgE不良结合。 我们已经发现，只有对某些片段特异性的单克隆抗体，如GLEGGSAQSQRAPDRVL（SEQ ID NO：2）和HSGQQQGLPRAAGGSVPHPR（SEQ ID NO：3）），可以有效地结合人B细胞上的mIgE，因此具有靶向 用于治疗IgE介导的疾病的B细胞。